X0306 4 2014-09-02 false 0000911326 SYNAGEVA BIOPHARMA CORP GEVA 0001532219 Quinn Anthony 33 HAYDEN AVE LEXINGTON MA 02421 false true false false EVP, CMO & Head of R&D Common Stock 2014-09-02 4 M false 10000 23 A 35595 D Common Stock 2014-09-02 4 S false 8600 69.88 D 26995 D Common Stock 2014-09-02 4 S false 400 70.5 D 26595 D Common Stock 2014-09-02 4 S false 700 71.96 D 25895 D Common Stock 2014-09-02 4 S false 300 72.88 D 25595 D Stock Option (Right to Buy) 23 2014-09-02 4 M false 10000 0 D 2021-12-20 Common Stock 10000 30000 D The sale of common stock reported in this Form 4 was effected pursuant to a Rule 10b5-1 plan adopted by the reporting person on December 26, 2013. The Stock Option granted the reporting person an option to purchase 50,000 shares of Common Stock (the "Shares"). 25% of the Shares vested and became exercisable on 12/20/2012, and 1/36 of the remainder of the Shares vest and become exercisable monthly thereafter. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $69.46 to $70.38. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $70.47 to $70.55. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $71.47 to $72.16. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. This transaction was executed in multiple trades through a broker-dealer at prices ranging from $72.69 to $73.04. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. /s/ Christopher J. Heberlig, Attorney-in-Fact 2014-09-04